Follow the money. All of it.
This interactive network map traces six simultaneous financial channels through which the pharmaceutical industry shapes American medicine — not through conspiracy, but through documented, legal, disclosed relationships that collectively create structural conflicts of interest at every level of the healthcare system.
$739 million in federal lobbying. $13.8 billion in drug ads. $710 million in NIH royalties paid to government scientists. $2.65 billion in payments to physicians. This interactive dashboard maps the documented financial relationships between pharmaceutical companies and the institutions that regulate, fund, publish, and broadcast their products — sourced entirely from government disclosures, FOIA records, and peer-reviewed research.
Pharma Financial Influence Network
A data-driven map of documented financial relationships between pharmaceutical companies and the institutions that regulate, fund, publish, and broadcast their products — sourced from government disclosures, FOIA records, and peer-reviewed research.
$0M
Federal Pharma Lobbying (2023)
$0B
Direct-to-Consumer Ad Spend (2023)
$0M
NIH Royalties Paid by Pharma (2022–23)
15–70%
FDA Advisory Meetings w/ Member COIs
0%
Clinical Trials Industry-Funded
#1
Lobbying Sector — 7 Years Running
🕸️ The Influence Network Map
Click any node to explore financial relationships. Hover connections for details.
Big Pharma deploys financial influence through six documented channels simultaneously: (1) $739M federal lobbying — #1 sector; (2) $13.8B DTC advertising to consumers and media; (3) $710M in royalties to NIH/NIAID scientists; (4) Research funding to academic medical centers; (5) $2.65B in payments to physicians; (6) Industry-funded clinical trials with 3.45× higher odds of favorable outcomes.
The pharmaceutical industry is the #1 federal lobbying sector for the 7th consecutive year, spending $739 million in 2023. Pharma employs approximately 1,500 lobbyists — nearly 3 per member of Congress. Sources: OpenSecrets 2024; NBC News Jan 27, 2024.
A systematic review (Value in Health, 2026) of 18 studies found COI prevalence among voting members ranging from 15% to over 70% of meetings. Public speakers with financial COIs were significantly more likely to provide favorable testimony (odds ratio 3.0–6.1). Sources: Gentilini et al., Value in Health 2026; FDA FY2024 Report.
$710 million paid by pharmaceutical companies to NIH in 2022–2023 (FOIA). $690 million went to NIAID. 260 NIAID scientists received royalty payments. 5,000+ individual payments since 2009 still redacted. Sources: OpenTheBooks/RealClearWire, July 2024.
87% of industry-funded trials vs 65% of independently-funded trials reported positive outcomes (OR: 3.45). Positive results published 92% of the time; negative results only 14%. Sources: Bekelman et al., JAMA 2003; Turner et al., NEJM 2008.
The US and New Zealand are the only two countries that permit DTC pharmaceutical advertising. Top 10 pharma companies spent $13.8B on DTC ads in 2023. CBO: 10% increase in DTC ads leads to 1–2.3% rise in drug spending. Sources: CSRxP 2025; Fierce Pharma 2024.
In 2022, pharma paid $2.65 billion to US physicians and hospitals — speaking fees, consulting fees, research payments, and meals. Physicians who receive payments are significantly more likely to prescribe the payer's drugs. Source: CMS Open Payments 2022.
Industry now funds more medical research than NIH. Researchers with industry ties are 3.5× more likely to report positive results. Industry's share of total US biomedical R&D has grown from 46% in 2000 to over 67%. Sources: Bekelman et al., JAMA 2003; NIH Budget Data.
🏛️ Regulatory Capture: FDA, NIH & the Revolving Door
Public officials legally moving between regulatory and industry roles — all from public financial disclosures.
The FDA–Pharma Revolving Door — Documented Cases
Scott Gottlieb: FDA Commissioner → Pfizer Board
Served as FDA Commissioner from May 2017 to April 2019. In June 2019 — just two months after leaving FDA — joined the board of directors of Pfizer Inc. FDA, under Gottlieb, approved 59 novel drugs in 2018 — the highest single-year total in FDA history. Pfizer's board seat pays approximately $300,000–$400,000 annually in cash and stock compensation.
Source: Pfizer Inc. 2019 Annual Report; STAT News 2019.
Stephen Hahn: FDA Commissioner → Moderna Investor Network
Served as FDA Commissioner from December 2019 to January 2021. In April 2021 — three months after leaving — joined Flagship Pioneering as Chief Medical Officer. Flagship Pioneering is the venture capital firm that founded and bankrolled Moderna. FDA under Hahn authorized Moderna's COVID-19 vaccine for Emergency Use Authorization in December 2020.
Source: Flagship Pioneering press release, April 2021; Reuters 2021.
Robert Califf: $2.7M in Pharma Fees → FDA Commissioner (Twice)
Before his first appointment as FDA Commissioner (2016), Robert Califf received approximately $2.7 million in consulting fees, speaker fees, and research support from pharmaceutical companies including Johnson & Johnson, Merck, Lilly, AstraZeneca, and Medtronic. He was reappointed as FDA Commissioner in 2022 and confirmed by the Senate 50-46. His pharma ties were a central point of contention during both confirmation hearings.
Source: BMJ 2016; US Senate confirmation records 2022.
Margaret Hamburg: FDA Commissioner → Insurance Industry
FDA Commissioner 2009–2015. After leaving FDA, took board positions in various healthcare and pharmaceutical-adjacent industries. During her tenure, she faced a lawsuit (later dismissed) alleging the FDA delayed action on a generic antibiotic to benefit companies in which her husband's hedge fund held investments.
Source: JAMA Internal Medicine; disclosed financial records.
⚠️ The Structural Issue: PDUFA User Fees
The Prescription Drug User Fee Act (PDUFA), first enacted in 1992 and renewed every 5 years, requires pharmaceutical companies to pay "user fees" to fund FDA drug review. In FY2024, user fees represent approximately 65% of FDA's drug review budget. Critics including former FDA scientists and bioethicists argue this creates a structural dependency: FDA's operating capacity is financially tied to the industry it regulates. FDA officials note that PDUFA fees are separate from approval decisions and that FDA maintains full scientific independence.
Source: FDA FY2024 Budget; Angell, NEJM 2004.
NIH Patent Royalties: $710 Million in 2022–2023
Data obtained via FOIA litigation — OpenTheBooks v. NIH, U.S. District Court
$710M
Total royalties paid by pharma to NIH (2022–2023)
$690M
To NIAID alone — 97% of total
260
NIAID scientists received royalty payments
5,000+
Payments since 2009 — names still REDACTED
Third-party royalties are payments made by private companies (including pharmaceutical companies) that use government-developed technologies. When NIH scientists develop technologies that are licensed to private companies, those scientists are entitled to share in the royalty income — a feature designed to incentivize innovation. The controversy: NIH initially refused FOIA requests for this data, leading to federal litigation by OpenTheBooks and Judicial Watch. When records were finally released, individual scientist names receiving 5,000+ payments were redacted — with NIH claiming the names are "trade secrets." This represents a sharp increase from $325 million in NIH royalties from 2009–2021.
Source: OpenTheBooks/Judicial Watch v. NIH; RealClearWire, July 1, 2024.
FDA Advisory Committee Conflicts of Interest: 26 Years of Research
Systematic literature review of 18 studies (1997–2022) — Value in Health, Gentilini et al., 2026
15–70%
Range of FDA advisory meetings with member financial COIs. High variance reflects different committees, years, and COI definitions across 18 analyzed studies.
~25%
Proportion of public speakers at FDA advisory meetings who disclosed financial COIs, primarily consulting fees, research funding, and stock ownership.
OR 3.0–6.1
Odds ratio for favorable testimony from public speakers with financial COIs vs. those without. (Gentilini et al., 2026)
What FDA Does About COIs
FDA requires all advisory committee members to complete detailed financial disclosure forms. Members with conflicts can be excluded from voting, granted a waiver if their expertise is deemed essential (18 USC §208), or required to recuse. In FY2024, FDA granted 12 waivers out of 762 total meeting participants (97.33% participated without waivers). Waivers are publicly disclosed. Critics argue the waiver system allows experts with industry ties to still participate in decisions that affect their financial interests.
Source: FDA FY2024 Advisory Committee Annual Report.
💰 Federal Lobbying & Direct-to-Consumer Advertising
Tracking the scale of pharma's financial presence in Washington and on American television.
Pharma Federal Lobbying Spend (2000–2023)
Source: OpenSecrets.org / NBC News Jan 2024
Direct-to-Consumer Drug Advertising: $13.8 Billion (2023)
The United States and New Zealand are the only two countries in the world that permit pharmaceutical direct-to-consumer advertising. The FDA first permitted DTC pharmaceutical advertising in 1997. Since then, annual pharma DTC spending has grown from $2.1 billion (1997) to $13.8 billion (2023) — a 557% increase. The top 10 pharma companies spent $13.8B total on advertising & promotion in 2023 in the US alone (CSRxP 2025). These advertising costs are IRS-deductible as business expenses, costing taxpayers an estimated $1.5–1.7 billion annually in lost tax revenue.
Top TV Drug Advertisers 2023
Source: iSpot.tv / Fierce Pharma 2024
CBO Finding
A 10% increase in DTC advertising leads to a 1–2.3% rise in drug spending.
Source: Congressional Budget Office
NBER Finding
NBER estimates drug spending increase from DTC could reach 5.4%.
Source: National Bureau of Economic Research
Tax Benefit
Pharma wrote off $13.8B in DTC ad costs in 2023, costing US taxpayers $1.5–1.7B in lost revenue.
Source: CSRxP 2025
Pharma Lobbying: Scale & Scope
1,500+
Pharma lobbyists in Washington (2023) — nearly 3 per member of Congress
$4.2B
Total US federal lobbying (2023 record) — pharma = 17.6%
7 Years
Consecutive years pharma has been #1 lobbying sector (2017–2023)
3
Primary targets: Senate Finance, Senate HELP, House E&C
🔬 Research Funding & Publication Bias
How financial incentives shape the medical evidence base.
Industry-sponsored clinical trials are 27% more likely to report favorable efficacy results and 34% more likely to reach favorable overall conclusions than independently-funded trials.
Source: Cochrane Database of Systematic Reviews, 2017 (75 meta-analyses)
Trial Outcomes: Industry vs. Independent Funding
87% report positive outcomes (BMJ 2003)
Difference: +22 percentage points. Pooled odds ratio: 3.45 (95% CI: 1.90–6.62). Source: Bekelman et al., JAMA 2003.
92% vs 14%
A landmark 2008 study in the New England Journal of Medicine (Turner et al.) analyzed 74 FDA-registered antidepressant trials. Among trials with positive results: 92% were published. Among trials with negative results: only 14% were published — and those that were published often presented the results as positive through selective framing. This selective publication means the medical literature dramatically overstates the efficacy of antidepressants — and likely many other drug classes.
Source: Turner et al., NEJM 2008.
Research Bias Mechanisms
Selective Outcome Reporting
Researchers pre-specify primary outcomes in protocols, then switch to reporting secondary outcomes that were positive. Clinical trial pre-registration at ClinicalTrials.gov (required since 2007) has reduced but not eliminated this practice.
Source: Chan et al., JAMA 2004.
Comparator Selection Bias
Industry trials often compare new drugs against suboptimal doses of competitor drugs or against placebo — stacking the comparison in favor of the new drug. This makes new (expensive, patented) drugs appear superior to existing (cheap, generic) alternatives.
Source: Rochon et al., JAMA 1994.
Publication Suppression
Negative trial results are significantly less likely to be submitted for publication, and when submitted, less likely to be accepted. This creates a filtered evidence base in which the medical literature systematically overstates benefits and understates harms.
Source: Dickersin et al., JAMA 1990; Turner et al., NEJM 2008.
Framing & Spin
Even when negative results are published, industry-funded studies are more likely to present them with positive framing in abstracts and conclusions. A study found 40% of industry-funded negative trials had positive-framing conclusions vs 12% of independent trials.
Source: Lundh et al., Cochrane 2017.
Who Funds Medical Research? (US Biomedical R&D)
Industry's share has grown from 46% in 2000 to over 67% today.
Source: NIH Budget; JAMA 2018.
📚 Sources & Methodology
All data sourced from official US government records, peer-reviewed research, disclosed financial filings, and FOIA-obtained documents.
Data Sources & Methodology
All data in this dashboard is sourced from official US government records, peer-reviewed research, disclosed financial filings, and FOIA-obtained documents. No claims of criminal conduct are made — all activities described are legal under current US law. This dashboard presents documented structural conflicts and financial relationships for public information.
1. OpenSecrets. "Lobbying: Pharmaceuticals/Health Products." 2024. opensecrets.org
2. NBC News / OpenSecrets. "Groups spent record $4.2B lobbying in 2023." January 27, 2024.
3. CSRxP. "Big Pharma DTC Advertising Analysis." 2025. Covering AbbVie, BMS, Eli Lilly, Pfizer + others.
4. Fierce Pharma. "Top TV drug ad spenders 2023." iSpot.tv data. 2024.
5. OpenTheBooks / RealClearWire. "NIH Hiding Details of $710M in Pandemic Royalties." July 1, 2024.
6. FDA. "FY2024 Annual Report on FDA Advisory Committee Vacancies and Public Disclosures."
7. Gentilini A, et al. "Conflicts of Interest in United States FDA Advisory Committees." Value in Health. 2026.
8. Lundh A, et al. "Industry sponsorship and research outcome." Cochrane Database Syst Rev. 2017.
9. Bekelman JE, et al. "Scope and Impact of Financial Conflicts of Interest in Biomedical Research." JAMA. 2003;289(4):454-465.
10. Turner EH, et al. "Selective Publication of Antidepressant Trials." NEJM. 2008;358(3):252-260.
11. BMJ. "Robert Califf's pharma industry financial ties." 2016.
12. Pfizer Inc. 2019 Annual Report / Board of Directors.
13. Flagship Pioneering. Press release: Stephen Hahn appointed CMO. April 2021.
14. CMS. Open Payments database. 2022. cms.gov/OpenPayments.
15. Congressional Budget Office. Drug Pricing and DTC Advertising Report. 2023.
